Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reiterated by equities researchers at Piper Jaffray Companies in a research report issued on Friday. They presently have a $12.00 price target on the stock. Piper Jaffray Companies’ price objective points to a potential upside of 5.26% from the stock’s previous close.

Several other analysts have also commented on the stock. BTIG Research upgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Monday, September 11th. TheStreet lowered shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a research note on Monday, July 24th. Credit Suisse Group downgraded shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $21.00 price objective (down previously from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, August 31st. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited currently has a consensus rating of “Hold” and a consensus target price of $26.29.

Shares of Teva Pharmaceutical Industries Limited (TEVA) traded down $2.62 on Friday, reaching $11.40. 49,114,477 shares of the company’s stock traded hands, compared to its average volume of 23,401,560. The company has a debt-to-equity ratio of 1.30, a current ratio of 0.94 and a quick ratio of 0.61. The company has a market capitalization of $11,409.68, a price-to-earnings ratio of 2.59, a price-to-earnings-growth ratio of 0.55 and a beta of 0.52.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 24.35% and a positive return on equity of 15.29%. The firm’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.25 earnings per share. analysts expect that Teva Pharmaceutical Industries Limited will post 4.11 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Piper Jaffray Companies Reaffirms Hold Rating for Teva Pharmaceutical Industries Limited (TEVA)” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/03/piper-jaffray-companies-reaffirms-hold-rating-for-teva-pharmaceutical-industries-limited-teva.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. Greylin Investment Mangement Inc. grew its stake in shares of Teva Pharmaceutical Industries Limited by 36.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock worth $9,783,000 after purchasing an additional 79,300 shares during the last quarter. Exane Derivatives acquired a new position in shares of Teva Pharmaceutical Industries Limited in the 3rd quarter worth approximately $571,000. Financial Counselors Inc. grew its stake in shares of Teva Pharmaceutical Industries Limited by 5.7% in the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after purchasing an additional 7,571 shares during the last quarter. PGGM Investments grew its stake in shares of Teva Pharmaceutical Industries Limited by 12.0% in the 2nd quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock worth $50,763,000 after purchasing an additional 163,292 shares during the last quarter. Finally, GAM Holding AG grew its stake in shares of Teva Pharmaceutical Industries Limited by 23.2% in the 2nd quarter. GAM Holding AG now owns 41,900 shares of the company’s stock worth $1,392,000 after purchasing an additional 7,900 shares during the last quarter. 56.55% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.